Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to $82.4 million.

  • Bio-Techne's Cash from Operations fell 229.41% to $82.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $249.3 million, marking a year-over-year decrease of 1818.08%. This contributed to the annual value of $287.6 million for FY2025, which is 382.13% down from last year.
  • Bio-Techne's Cash from Operations amounted to $82.4 million in Q4 2025, which was down 229.41% from $27.6 million recorded in Q3 2025.
  • Bio-Techne's 5-year Cash from Operations high stood at $122.0 million for Q2 2021, and its period low was $27.6 million during Q3 2025.
  • Its 5-year average for Cash from Operations is $73.7 million, with a median of $75.2 million in 2021.
  • Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 17242.08% in 2021, then tumbled by 5682.36% in 2025.
  • Quarter analysis of 5 years shows Bio-Techne's Cash from Operations stood at $101.0 million in 2021, then tumbled by 36.25% to $64.4 million in 2022, then grew by 29.09% to $83.1 million in 2023, then rose by 1.48% to $84.3 million in 2024, then dropped by 2.29% to $82.4 million in 2025.
  • Its last three reported values are $82.4 million in Q4 2025, $27.6 million for Q3 2025, and $98.2 million during Q2 2025.